EPIX Announces European Approval of Vasovist
5th Oct 2005, 12:54 GMT
EPIX Pharmaceuticals, a developer of innovative pharmaceuticals for MRI, announced that its worldwide marketing partner, Schering AG, Germany, has received the approval of Vasovist in all 25 member states of the EU.
EPIX Announces European Approval of Vasovist related news:
- Market Pulse: EPIX Pharma gets lift from Vasovist approval in Europe — Angiography/ Cardiac Cath News from StratCenter.com
- Epix, Schering Get EU Vasovist OK — Financial News News from StratCenter.com
- European approval for Epix's vascular visualization drug — Pharmaceutical Business Review Online
- Schering AG Receives EU Approval for Novel Contrast Agent Vasovist — Angiography/ Cardiac Cath News from StratCenter.com
- Schering erhält EU-Zulassung für "Vasovist" — Finanztreff.de / TOPTHEMEN
- Epix gets EU green light to sell imaging compound — bizjournals.com Health Care:Pharmaceuticals headlines
- Schering AG Receives EU Approval for Novel Contrast Agent Vasovist(R) — PR Newswire: All Releases
- JNJ's Remicade Gets Expanded EU Approval — Pharmaceuticals News from StratCenter.com
- Teva Announces Approval of Glimepiride Tablets — Pharmaceuticals News from StratCenter.com
- Teva Announces Tentative Approval of Gatifloxacin Tablets — Financial News News from StratCenter.com
Latest news from Angiography/ Cardiac Cath News from StratCenter.com:
- Thinking Systems Releases Enhanced PET-CT Functions for Its ThinkingPACS
- Tallahassee Memorial Hospital at the Forefront in Treatment of Heart Attack Patients
- Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease